Novo Nordisk
NVO
#22
Rank
โ‚ฌ382.24 B
Marketcap
82,01ย โ‚ฌ
Share price
-17.83%
Change (1 day)
-12.78%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Novo Nordisk (NVO) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : โ‚ฌ40.02 Billion

According to Novo Nordisk's latest financial reports the company's total liabilities are โ‚ฌ40.02 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Novo Nordisk - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31โ‚ฌ27.85 B31.52%
2022-12-31โ‚ฌ21.18 B27.3%
2021-12-31โ‚ฌ16.63 B51.72%
2020-12-31โ‚ฌ10.96 B20.45%
2019-12-31โ‚ฌ9.10 B15.35%
2018-12-31โ‚ฌ7.89 B11.8%
2017-12-31โ‚ฌ7.05 B0.33%
2016-12-31โ‚ฌ7.03 B17.1%
2015-12-31โ‚ฌ6.00 B21.69%
2014-12-31โ‚ฌ4.93 B32.64%
2013-12-31โ‚ฌ3.72 B10.92%
2012-12-31โ‚ฌ3.35 B-8.19%
2011-12-31โ‚ฌ3.65 B11.49%
2010-12-31โ‚ฌ3.27 B28.29%
2009-12-31โ‚ฌ2.55 B7.69%
2008-12-31โ‚ฌ2.37 B13.71%
2007-12-31โ‚ฌ2.08 B6.62%
2006-12-31โ‚ฌ1.95 B2.39%
2005-12-31โ‚ฌ1.91 B29.41%
2004-12-31โ‚ฌ1.47 B19.61%
2003-12-31โ‚ฌ1.23 B7.17%
2002-12-31โ‚ฌ1.15 B-17.35%
2001-12-31โ‚ฌ1.39 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚ฌ122.44 B 205.95%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ59.12 B 47.74%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ73.77 B 84.34%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ58.70 B 46.67%๐Ÿ‡ซ๐Ÿ‡ท France